Search results
Causes of Skin Changes in Leukocytoclastic Vasculitis
Verywell Health via Yahoo News· 10 months agoLeukocytoclastic vasculitis, also known as hypersensitivity vasculitis, involves inflamed small...
ChemoCentrix Spikes 110% on Amgen Acquisition Deal
GuruFocus.com via Yahoo Finance· 2 years agoOn Thursday, shares of ChemoCentryx Inc. (NASDAQ:CCXI) shot up more than 110% before closing the day at $50.43 on the news that the small-cap biotech...
ChemoCentryx's (CCXI) Tavneos Aids Growth, Overdependence a Woe
Zacks via Yahoo Finance· 2 years agoChemoCentryx (CCXI) has only one product approved for sale in its portfolio, Tavneos. Nevertheless,...
Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates
Zacks via Yahoo Finance· 2 years agoThe biotech sector has been in the spotlight in the past week on earnings releases. Acquisitions and...
Amgen Aims To Stanch Generic Losses With $3.7 Billion ChemoCentryx Buyout
Investor's Business Daily· 2 years agoAmgen agreed to buy ChemoCentryx for $3.7 billion on Thursday, leading CCXI stock to rocket....
ChemoCentryx Stock More Than Doubles On $4B Buyout
Benzinga via Yahoo Finance· 2 years agoAmgen Inc (NASDAQ: AMGN) has agreed to acquire ChemoCentryx Inc (NASDAQ: CCXI) for $52 per share in cash, representing an enterprise value of...
Aerie (AERI) Rallies 205.6% in the Past Three Months: Here's Why
Zacks via Yahoo Finance· 2 years agoAerie (AERI) shares have skyrocketed in the past three months after the company announced its...
Amgen (AMGN) Q2 Earnings Beat Estimates, 2023 View Raised
Zacks via Yahoo Finance· 11 months agoAmgen AMGN reported second-quarter 2023 earnings of $5.00 per share, which beat the Zacks Consensus...
Amgen (AMGN) Beats on Q3 Earnings & Sales, Tweaks 2022 View
Zacks via Yahoo Finance· 2 years agoAmgen AMGN reported third-quarter 2022 earnings of $4.70 per share, which beat the Zacks Consensus...
Amgen (AMGN) Q4 Earnings Top, Horizon Drugs Drive Sales
Zacks via Yahoo Finance· 4 months agoAmgen AMGN reported fourth-quarter 2023 adjusted earnings of $4.71 per share, which beat the Zacks...